Perhexiline maleate
Modify Date: 2024-01-02 13:40:53
Perhexiline maleate structure
|
Common Name | Perhexiline maleate | ||
|---|---|---|---|---|
| CAS Number | 6724-53-4 | Molecular Weight | 393.56000 | |
| Density | N/A | Boiling Point | 574.1ºC at 760 mmHg | |
| Molecular Formula | C23H39NO4 | Melting Point | 181-183ºC | |
| MSDS | Chinese USA | Flash Point | 301ºC | |
Use of Perhexiline maleatePerhexiline maleate is a potent carnitine palmitoyltransferase 1 (CPT 1) inhibitor with IC50s of 77 and 148 μM for rat heart and liver CPT 1, respectively. |
| Name | (Z)-but-2-enedioic acid,2-(2,2-dicyclohexylethyl)piperidine |
|---|---|
| Synonym | More Synonyms |
| Description | Perhexiline maleate is a potent carnitine palmitoyltransferase 1 (CPT 1) inhibitor with IC50s of 77 and 148 μM for rat heart and liver CPT 1, respectively. |
|---|---|
| Related Catalog | |
| Target |
IC50: 77 μM (Rat heart CPT 1), 148 μM (Rat liver CPT 1)[1] |
| In Vitro | At 24, 48 and 72 h of treatment with 0.01 and 1 μM of Perhexiline , NDM29 ncRNA expression level in SH-SY5Y cells is progressively increased, reaching a peak after 48 hours of treatment. Perhexiline treatment increases the susceptibility of NB cells to antiblastic treatments. Co-administration of Perhexiline maleate potentiates the efficacy of cisplatin to reduce the in vitro clonogenic potential of NB cells[2]. |
| In Vivo | The co-administration of Perhexiline and cisplatin yields a clear enhancement of antitumor effects, resulting in a significantly improved progression-free survival as compared with mice treated with DMSO. Perhexiline favors NB cell transition to differentiated phenotype[2]. |
| Cell Assay | The effect of antitumoral drugs on neuroblastoma cell survival is evaluated using the MTT assay. Approximately 24 hours after plating, cells are exposed to Perhexiline maleate (0.01 μM) for 48 hours at 37°C. Cytotoxicity is expressed as the percentage of cells surviving in relation to untreated cells[2]. |
| Animal Admin | Mice: In protocol a, 21 mice are divided in 4 groups: control vehicle group: DMSO; cisplatin (3 mg/kg/dose) treated group; Perhexiline (1 mg/kg/dose) treated group and; Perhexiline (1 mg/kg/dose) and cisplatin (3 mg/kg/dose) treated group. In protocol b, 20 mice are divided in 4 groups: control vehicle group: DMSO; Perhexiline (3 mg/kg/dose) treated group; cisplatin (5 mg/kg/dose) treated group; Perhexiline (3 mg/kg/dose) and cisplatin (5 mg/kg/dose) treated group[2]. |
| References |
| Boiling Point | 574.1ºC at 760 mmHg |
|---|---|
| Melting Point | 181-183ºC |
| Molecular Formula | C23H39NO4 |
| Molecular Weight | 393.56000 |
| Flash Point | 301ºC |
| Exact Mass | 393.28800 |
| PSA | 86.63000 |
| LogP | 5.33600 |
| Appearance of Characters | white to tan |
| Storage condition | -20?C Freezer, Under Inert Atmosphere |
| Water Solubility | DMSO: ≥5mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| RIDADR | NONH for all modes of transport |
|---|---|
| WGK Germany | 2 |
| RTECS | TM7068000 |
| HS Code | 2933399090 |
|
~%
Perhexiline maleate CAS#:6724-53-4 |
| Literature: US4191828 A1, ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Torsade de pointes associated with perhexiline maleate therapy.
Aust. N. Z. J. Med. 20(6) , 818-20, (1990) Multiform ventricular tachycardia (torsade de pointes) is a recognised proarrhythmic effect of drugs which prolong the QT interval. A case is now described for the first time where torsade de pointes ... |
|
|
Further studies on the pharmacokinetics of perhexiline maleate in humans.
Xenobiotica 16(1) , 63-8, (1986) We have performed single-dose pharmacokinetic studies on perhexiline in eight young volunteers, each given 300 mg of Pexid orally, using an h.p.l.c. method for the separation and quantification of the... |
|
|
Stimulatory effect of perhexiline maleate on the basal and LHRH-stimulated luteinizing hormone release from rat pituitary cell aggregates in vitro.
Res. Commun. Mol. Pathol. Pharmacol. 87(2) , 115-23, (1995) Perhexiline maleate (PM) is an anti-anginal agent of amphiphilic character involved in lipidosis disorders. Experiments were carried out to study PM action on LH release from rat anterior pituitary ce... |
| perhexilline maleate |
| Perhexiline maleate (USAN) |
| EINECS 229-775-5 |
| Pexid |
| 2-(2,2-Dicyclohexylethyl)piperidine maleate |
| DSSTox_CID_1114 |
| perhexilene maleate |
| Perhexiline maleate |